In Re: Xarelto (Rivaroxaban) Products Liability Litigation

  1. August 17, 2017

    Xarelto Patient Says Jury Can Decide Claims

    A woman claiming that the blood thinner Xarelto caused gastrointestinal bleeding that required her hospitalization told a Louisiana federal judge on Thursday that Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. can't put an end to her bellwether trial.

  2. August 14, 2017

    J&J, Bayer Ask To Strike Doc's Testimony In Xarelto Trial

    Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. on Monday asked the Louisiana federal judge overseeing the third bellwether trial over the blood thinner Xarelto to strike testimony from a physician about a proposed label change redlined by the U.S. Food and Drug Administration. 

  3. July 24, 2017

    Janssen, Bayer Must Face Third Bellwether In Xarelto MDL

    A Louisiana federal judge on Friday refused to grant Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. a quick win in a patient's suit accusing them of not warning about the possibility of dangerous internal bleeding associated with the blood thinner Xarelto, allowing the third bellwether trial in the multidistrict litigation to move forward. 

  4. June 13, 2017

    Patient In First Xarelto Bellwether Wants New Trial

    A patient who lost the first bellwether trial in multidistrict litigation over allegations that Janssen and Bayer’s blood thinner Xarelto causes unstoppable bleeding has asked a Louisiana federal court for a new trial, arguing a pre-trial order blocked the jury from getting both sides of the story.

  5. June 12, 2017

    Bayer, Janssen Win 2nd Xarelto Bellwether Trial

    A New Orleans federal jury on Monday awarded a defense verdict to Janssen and Bayer in the second bellwether trial in multidistrict litigation over unstoppable bleeding allegedly caused by their blood thinner Xarelto.

  6. June 09, 2017

    Bayer, Janssen Say Blood Thinner Warning Claim Preempted

    Bayer and Janssen urged a Louisiana federal judge Thursday to toss patients' last remaining failure-to-warn claim in multidistrict litigation alleging their blood thinner Xarelto caused irreversible bleeding, saying they couldn't have changed the treatment's label to recommend a diagnostic test without approval by the U.S. Food and Drug Administration.

  7. May 23, 2017

    Patients Slam Bayer, Janssen's Bid To Cut Xarelto Claims

    Patients in multidistrict litigation claiming Janssen and Bayer's blood thinner Xarelto caused irreversible bleeding told a Louisiana federal court Tuesday the companies should not be able to escape any claims that rely on allegations the patients previously dropped.

  8. May 03, 2017

    Bayer, Janssen Score Win In 1st Xarelto Trial

    A Louisiana federal jury on Wednesday sided with Janssen and Bayer in the first bellwether trial in multidistrict litigation over unstoppable bleeding allegedly caused by their blood thinner Xarelto.

  9. April 13, 2017

    Janssen, Bayer Lose Preemption Bids As Xarelto Trial Nears

    Days before a first bellwether trial begins in multidistrict litigation over the alleged dangers of blood thinner Xarelto, a Louisiana federal judge on Wednesday refused to drop some claims against Bayer AG and Janssen Pharmaceuticals Inc., saying they can't necessarily blame U.S. Food and Drug Administration red tape for their lack of label updates or for any noncompliance with Louisiana law.

  10. April 13, 2017

    Janssen, Bayer Call Xarelto MDL Exclusion Request Too Broad

    Janssen and Bayer on Wednesday urged a Louisiana federal court not to limit what they're allowed to testify about during the first bellwether trial in multidistrict litigation over unstoppable bleeding allegedly caused by their blood thinner Xarelto, saying the patient's requested exclusion is "impermissibly broad in scope and imprecise."